Pediatric inflammatory bowel disease is a disease of invisible progression. A child with Crohn’s disease who achieved clinical remission on prednisone can eat normally, play normally, and report no abdominal pain while the bowel wall continues its transmural inflammatory process — forming granulomas, depositing fibrosis, slowly narrowing the intestinal lumen. A child with ulcerative colitis who has not had a symptomatic flare in three years can be accumulating oxidative DNA damage in mucosal cells that are driving toward dysplasia. A child with Crohn’s disease and completely normal serum CRP and normal stools can have fecal calprotectin 380 μg/g and active mucosal neutrophil inflammation that will drive structural complications if not addressed.
Spanish for pediatric inflammatory bowel disease clinic nurses begins with recognizing three structural gaps between what families observe and what the clinical team is managing at the molecular and histological level. First: if the child is in clinical remission on prednisone and feels completely well, why is a powerful biologic now being started? Second: if the child has had no symptoms for three years and mesalamine is clearly controlling the colitis, why is an invasive colonoscopy being scheduled? Third: if the blood test is normal and the child’s stools are formed and she reports no pain, why is the fecal calprotectin result being used to push for another colonoscopy? The answers to each question require making an invisible biological mechanism visible — the gap between symptom control and mucosal healing in Crohn’s disease, the asymptomatic molecular pathway of UC-associated dysplasia, and the distinct informational content of serum CRP versus fecal calprotectin as markers of mucosal disease activity.
The three conversations in this post take place in Houston, San Antonio, and Dallas, in the pediatric gastroenterology clinics of three children’s hospitals. Each involves a family that is engaged, medically experienced, and genuinely confused by a recommendation that appears inconsistent with what they observe in their child’s daily function and laboratory results. Each involves a nurse explaining the invisible mechanism in bilingual Spanish-English dialogue.
Scenario 1: Lucía Morales-Espinoza — Houston, Texas
Pediatric IBD nurse Valentina Herrera-Torres and the parents who cannot understand why infliximab is needed when prednisone already achieved clinical remission
Lucía is eleven years old. She was born in Houston to Elena Morales-Torres, forty, a preschool teacher, and Javier Espinoza-García, forty-three, a landscaping contractor. Fourteen months ago, Lucía began having abdominal cramping, loose stools with occasional blood, and lost 4.2 kilograms over six weeks. Her pediatrician referred her to pediatric gastroenterology. Colonoscopy showed ileocolonic Crohn’s disease with deep ulcers in the terminal ileum and scattered aphthous ulcers in the colon. Biopsy confirmed transmural inflammation with granulomas in the terminal ileum. MRI enterography showed mural thickening and increased enhancement of a 12-cm segment of terminal ileum without stricture. Her PCDAI at diagnosis was 45 — moderate-to-severe disease.
She was treated with prednisone 40 mg daily for two weeks, then tapered over six weeks. By week eight she was in complete clinical remission — no abdominal pain, formed stools, weight regained, PCDAI 5. The gastroenterology team initiated azathioprine 2 mg/kg/day at week four of prednisone. Ten weeks later, azathioprine thiopurine metabolite levels are therapeutic, but the plan presented at today’s visit is to add infliximab 5 mg/kg infusions every eight weeks, as a combination induction strategy.
Elena opens the visit: “Quiero entender por qué necesita el infliximab. Lucía lleva diez semanas sin síntomas — come bien, no tiene dolor, recuperó el peso. La prednisona funcionó perfectamente. El médico dice que el azatioprina también está funcionando. ¿Por qué agregar ahora un medicamento tan fuerte?”
(I want to understand why she needs infliximab. Lucía has been without symptoms for ten weeks — she eats well, has no pain, regained her weight. Prednisone worked perfectly. The doctor says azathioprine is also working. Why add such a powerful medication now?)
Javier adds: “Hemos leído sobre los efectos secundarios del infliximab — riesgo de infecciones, el sistema inmune suprimido. Si Lucía está bien, ¿no es mejor esperar a ver si el azatioprina solo es suficiente?”
(We have read about the side effects of infliximab — risk of infections, suppressed immune system. If Lucía is well, isn't it better to wait and see if azathioprine alone is enough?)
Nurse Valentina Herrera-Torres pulls her chair forward. “Entiendo perfectamente por qué esa pregunta tiene mucho sentido. Lucía está bien — eso es real y es importante. Pero quiero explicarles algo sobre la diferencia entre cómo se siente Lucía y cómo está la pared de su intestino. Porque esas dos cosas pueden ser muy diferentes en la enfermedad de Crohn.”
(I completely understand why that question makes a lot of sense. Lucía is well — that is real and it is important. But I want to explain something about the difference between how Lucía feels and how the wall of her intestine is. Because those two things can be very different in Crohn's disease.)
Elena: “¿Qué quiere decir?”
(What do you mean?)
“La enfermedad de Crohn no está solo en la superficie del intestino — la parte que está en contacto con los alimentos. Está en todas las capas de la pared del intestino: en la mucosa, debajo de la mucosa, en el músculo de la pared, y a veces llega hasta el exterior del intestino. Cuando la prednisona suprime la inflamación, suprime los síntomas porque reduce la inflamación en la superficie — los néutrofilos que estaban causando ulceraciones en la mucosa se reducen, el dolor y la diarrea mejoran. Pero la prednisona no llega al proceso más profundo que está en las capas internas de la pared del intestino. Ese proceso, llamado inflamación transmural, es el que produce complicaciones a largo plazo en la enfermedad de Crohn.”
(Crohn's disease is not only in the surface of the intestine — the part in contact with food. It is in all layers of the bowel wall: in the mucosa, below the mucosa, in the muscle of the wall, and sometimes reaches the outside of the intestine. When prednisone suppresses the inflammation, it suppresses the symptoms because it reduces the inflammation at the surface — the neutrophils that were causing ulcerations in the mucosa are reduced, the pain and diarrhea improve. But prednisone does not reach the deeper process that is in the inner layers of the bowel wall. That process, called transmural inflammation, is what produces long-term complications in Crohn's disease.)
Javier: “¿Qué tipo de complicaciones?”
(What type of complications?)
“Hay dos tipos principales. La primera es que la inflamación profunda produce fibrosis — tejido cicatricial — en la pared del intestino. Con el tiempo, ese tejido cicatricial hace que la pared del intestino se engruse y el canal del intestino se estreche. Llamamos a eso enfermedad estenosante: el intestino se hace tan angosto que los alimentos no pueden pasar bien. Lucía puede sentirse completamente bien durante meses o años mientras ese estrechamiento ocurre, y de repente tener dolor severo después de comer porque el intestino está obstruido. Muchos de esos niños terminan necesitando cirugía para quitar el segmento estenado. La segunda complicación es que la inflamación profunda a veces atraviesa completamente la pared del intestino y forma un canal anormal hacia otro órgano o hacia la piel — eso se llama una fístula. O forma una bolsa llena de pus dentro del abdomen — un absceso. Esas complicaciones también requieren cirugía o drenaje.”
(There are two main types. The first is that the deep inflammation produces fibrosis — scar tissue — in the bowel wall. Over time, that scar tissue makes the bowel wall thicken and the bowel channel narrow. We call that stricturing disease: the intestine becomes so narrow that food cannot pass well. Lucía can feel completely well for months or years while that narrowing occurs, and suddenly have severe pain after eating because the intestine is obstructed. Many of those children end up needing surgery to remove the narrowed segment. The second complication is that the deep inflammation sometimes penetrates completely through the bowel wall and forms an abnormal channel toward another organ or toward the skin — that is called a fistula. Or it forms a pocket filled with pus inside the abdomen — an abscess. Those complications also require surgery or drainage.)
Elena is quiet for a moment. “¿Eso puede pasar aunque Lucía se sienta bien?”
(That can happen even if Lucía feels well?)
“Sí, exactamente. Los estudios en niños con la enfermedad de Crohn muestran que más del cincuenta por ciento de los que son tratados solo con esteroides — sin biología de mantenimiento — desarrollan enfermedad estenosante o penetrante dentro de los primeros cinco años del diagnóstico. Muchos de ellos se sintieron bien entre brotes. El proceso de fibrosis ocurrió silenciosamente mientras estaban en remisión clínica.”
(Yes, exactly. Studies in children with Crohn's disease show that more than fifty percent of those treated only with steroids — without biologic maintenance — develop stricturing or penetrating disease within the first five years after diagnosis. Many of them felt well between flares. The fibrosis process occurred silently while they were in clinical remission.)
Javier: “¿Y el infliximab llega a esa inflamación profunda?”
(And infliximab reaches that deep inflammation?)
“Sí. El infliximab es un anticuerpo que va directamente al TNF-alfa — una proteína clave que mantiene activo el proceso inflamatorio profundo en la pared del intestino de Lucía. Cuando el infliximab neutraliza el TNF-alfa, suprime tanto la inflamación superficial que produce los síntomas como la inflamación transmural que produce la fibrosis a largo plazo. Los estudios en niños con la enfermedad de Crohn — el estudio REACH y otros — muestran que el infliximab puede lograr la curación de la mucosa: que cuando se hace una colonoscopía después del tratamiento, el intestino se ve completamente sano por dentro, sin ulceraciones ni signos de inflamación activa. Esa curación de la mucosa es lo que predice que el intestino no va a desarrollar esas complicaciones estructurales a largo plazo.”
(Yes. Infliximab is an antibody that goes directly to TNF-alpha — a key protein that keeps the deep inflammatory process active in Lucía's bowel wall. When infliximab neutralizes TNF-alpha, it suppresses both the surface inflammation that produces symptoms and the transmural inflammation that produces fibrosis long-term. Studies in children with Crohn's disease — the REACH trial and others — show that infliximab can achieve mucosal healing: that when a colonoscopy is done after treatment, the intestine looks completely healthy inside, without ulcerations or signs of active inflammation. That mucosal healing is what predicts that the intestine will not develop those structural complications long-term.)
Elena: “O sea que el azatioprina solo no puede hacer eso.”
(So azathioprine alone cannot do that.)
“El azatioprina ayuda, y es parte del plan — ayuda al infliximab a funcionar mejor y reduce el riesgo de que el cuerpo de Lucía forme anticuerpos contra el infliximab. Pero el azatioprina solo tiene tasas de curación de la mucosa significativamente más bajas que la combinación. Los estudios pediátricos muestran que la combinación de infliximab más azatioprina produce curación de la mucosa en el sesenta a setenta por ciento de los niños con la enfermedad de Crohn moderada a severa — frente al veinte a treinta por ciento con azatioprina solo. Y Lucía tiene enfermedad ileocólica con granulomas y con cambios en la RM de enterografía que indican inflamación transmural activa al momento del diagnóstico. Ese es exactamente el perfil en que el beneficio de la biología temprana es más claro.”
(Azathioprine helps, and it is part of the plan — it helps infliximab work better and reduces the risk that Lucía's body forms antibodies against infliximab. But azathioprine alone has significantly lower mucosal healing rates than the combination. Pediatric studies show that the combination of infliximab plus azathioprine produces mucosal healing in 60 to 70 percent of children with moderate to severe Crohn's disease — compared to 20 to 30 percent with azathioprine alone. And Lucía has ileocolonic disease with granulomas and MRI enterography changes indicating active transmural inflammation at the time of diagnosis. That is exactly the profile in which the benefit of early biologic therapy is clearest.)
Javier: “¿Y los efectos secundarios que leímos?”
(And the side effects we read about?)
“Los efectos secundarios existen y son reales — no los voy a minimizar. El más importante es un mayor riesgo de infecciones bacterianas y virales porque el sistema inmune está un poco más suprimido. Lo que le vamos a pedir a Lucía es que esté al día en vacunas antes de empezar el tratamiento, que consulte rápido si tiene fiebre durante el tratamiento, y que evite el contacto con personas con varicela activa. Hay también un riesgo pequeño de reacciones durante la infusión, que por eso se hacen en un centro con monitoreo. El equipo que va a administrar el infliximab está entrenado para reconocer y manejar esas reacciones. Comparando: el riesgo de esas complicaciones que mencionamos — estenosis, fístula, cirugía — en un niño con la enfermedad de Crohn de Lucía sin biología de mantenimiento es mayor que el riesgo de los efectos secundarios del infliximab cuando se usa correctamente con el monitoreo adecuado.”
(Side effects exist and are real — I am not going to minimize them. The most important is a somewhat increased risk of bacterial and viral infections because the immune system is slightly more suppressed. What we will ask of Lucía is to be up to date on vaccines before starting treatment, to consult quickly if she has fever during treatment, and to avoid contact with people with active chickenpox. There is also a small risk of reactions during the infusion, which is why they are done in a center with monitoring. The team that will administer infliximab is trained to recognize and manage those reactions. Comparing: the risk of those complications we mentioned — stricture, fistula, surgery — in a child with Lucía's Crohn's disease without biologic maintenance is greater than the risk of infliximab side effects when used correctly with adequate monitoring.)
Elena takes a deep breath. “La prednisona calló los síntomas pero no curó el intestino por dentro.”
(Prednisone silenced the symptoms but did not cure the intestine from the inside.)
“Exactamente. Y esa es la diferencia que define todo el tratamiento de mantenimiento en la enfermedad de Crohn en niños. La meta no es que Lucía se sienta bien — eso es el punto de partida. La meta es que la colonoscopía de control, que vamos a hacer en seis meses, muestre un intestino completamente cicatrizado por dentro. Ese es el resultado que le da a Lucía la mejor probabilidad de no necesitar cirugía y de tener una calidad de vida normal en los próximos años.”
(Exactly. And that is the difference that defines all maintenance treatment in Crohn's disease in children. The goal is not that Lucía feels well — that is the starting point. The goal is that the monitoring colonoscopy, which we will do in six months, shows an intestine completely healed from the inside. That is the outcome that gives Lucía the best probability of not needing surgery and having a normal quality of life in the coming years.)
Javier nods slowly. “No lo habíamos pensado así — que estar bien no significa que el intestino esté curado. ¿Cuándo sabremos si el infliximab está funcionando de verdad?”
(We had not thought about it that way — that feeling well does not mean the intestine is healed. When will we know if infliximab is truly working?)
“La colonoscopía a los seis meses nos lo dirá. También vamos a medir la calprotectina fecal a las doce semanas — que es una prueba en las heces que detecta si hay inflamación activa en el intestino incluso cuando no hay síntomas. Si la calprotectina baja a menos de ciento cincuenta y la colonoscopía muestra mucosa cicatrizada, eso es curación de la mucosa y el tratamiento está funcionando. En ese punto tenemos los datos para confirmar que el plan es correcto para Lucía.”
(The colonoscopy at six months will tell us. We will also measure fecal calprotectin at twelve weeks — which is a test in the stool that detects whether there is active inflammation in the intestine even when there are no symptoms. If calprotectin drops below one hundred fifty and the colonoscopy shows healed mucosa, that is mucosal healing and the treatment is working. At that point we have the data to confirm that the plan is right for Lucía.)
Scenario 2: Marco Torres-Ramírez — San Antonio, Texas
Pediatric IBD nurse Elena Morales-García and the parents who cannot understand why surveillance colonoscopy is required when their son has been in complete remission for three years
Marco is fifteen years old. He was diagnosed with extensive ulcerative colitis — E3 pancolitis — at age nine in San Antonio. His parents are Rosa Torres-Herrera, forty-four, a hotel housekeeper, and Alejandro Ramírez-Cruz, forty-six, a truck driver. Marco was hospitalized with his first flare at age nine — bloody diarrhea twelve times per day, fever, CRP 84 mg/L, albumin 2.8 g/dL, a Mayo score of 11. He was treated with intravenous methylprednisolone, responded, and was discharged on oral prednisone taper plus mesalamine 4 g daily.
Over the following six years, Marco had two additional moderate flares controlled with outpatient prednisone tapers. For the past three years, he has been on mesalamine 4 g daily with no symptomatic flares. His most recent Mayo score is 0: no blood in stool, no urgency, normal stool frequency. His fecal calprotectin is 78 μg/g. He is now fifteen, six years after diagnosis, and the surveillance colonoscopy schedule based on his disease duration and extent begins at eight years after diagnosis but the team is scheduling it proactively now given his pancolitis extent and prior disease activity.
Rosa opens the appointment: “Marco está completamente bien — tres años sin brotes, sin sangre, sin urgencia. Estamos muy contentos con el mesalamina. ¿Por qué necesita una colonoscopía ahora? ¿No es solo para ver si hay un brote?”
(Marco is completely well — three years without flares, without blood, without urgency. We are very happy with the mesalamine. Why does he need a colonoscopy now? Isn't it only to see if there is a flare?)
Alejandro: “La colonoscopía no es un examen pequeño para un adolescente — la preparación, el tiempo fuera de la escuela, la sedación. Si Marco está bien, ¿no podemos esperarnos más?”
(Colonoscopy is not a small procedure for an adolescent — the preparation, the time out of school, the sedation. If Marco is well, can't we wait longer?)
Nurse Elena Morales-García acknowledges Marco, who is scrolling on his phone and appears unconcerned. “Marco lleva tres años sin brótes y eso es un éxito real — el mesalamina está controlando la actividad de la colitis muy bien. Tienen toda la razón. La colonoscopía de hoy no es para buscar un brote. Es para buscar algo diferente, que puede ocurrir en la colitis ulcerativa aunque no haya brotes y aunque el paciente se sienta perfectamente.”
(Marco has had three years without flares and that is a real success — mesalamine is controlling the colitis activity very well. You are completely right. Today's colonoscopy is not to look for a flare. It is to look for something different, which can occur in ulcerative colitis even without flares and even when the patient feels perfectly well.)
Rosa: “¿Qué cosa diferente?”
(What different thing?)
“Los cambios en las células del intestino que, después de muchos años de colitis, pueden eventualmente convertirse en cáncer. Lo llamamos displasia — células que tienen cambios en su ADN pero que todavía no son cáncer. Si los encontramos en esta etapa, los podemos tratar. El problema es que esos cambios no producen síntomas. Marco puede sentirse perfectamente bien mientras esos cambios ocurren. No va a sentir dolor, no va a ver sangre, no va a tener urgencia por eso. Es un proceso completamente diferente a los brotes de la colitis.”
(The changes in the cells of the intestine that, after many years of colitis, can eventually become cancer. We call it dysplasia — cells that have changes in their DNA but that are not yet cancer. If we find them at this stage, we can treat them. The problem is that those changes do not produce symptoms. Marco can feel perfectly well while those changes occur. He will not feel pain, will not see blood, will not have urgency because of that. It is a completely different process from colitis flares.)
Alejandro looks up. “¿Por qué la colitis produce eso?”
(Why does colitis produce that?)
“Cuando el intestino grueso tiene inflamación durante muchos años — como la tuvo Marco con sus brotes — las células del sistema inmune en la mucosa producen unas moléculas llamadas radicales libres, que son subproductos químicos de la inflamación. Esos radicales libres pueden dañar el ADN de las células que recubren el intestino. Cada brote añade un poco más de ese daño. Después de muchos años, ese daño acumulado puede producir cambios en genes que normalmente previenen el cáncer. Las células que tienen ese daño se llaman células diplásicas.”
(When the large intestine has inflammation for many years — as Marco had with his flares — the immune cells in the mucosa produce molecules called free radicals, which are chemical byproducts of inflammation. Those free radicals can damage the DNA of the cells that line the intestine. Each flare adds a bit more of that damage. After many years, that accumulated damage can produce changes in genes that normally prevent cancer. The cells that have that damage are called dysplastic cells.)
Rosa: “¿Y esas células no se ven cuando Marco tiene un brote?”
(And those cells are not seen when Marco has a flare?)
“No — y ese es el punto más importante. Las células diplásicas muchas veces están en mucosa que se ve normal por fuera. En el cáncer de colon común que no está relacionado con la colitis, hay un pólipo visible que el médico puede ver directamente con el colonoscopio y quitar. Pero en la colitis ulcerativa, los cambios displaásticos pueden estar distribuidos en toda la mucosa del colon, en zonas que se ven completamente normales. Si no se toman biopsias sistemáticas de esas zonas aparentemente normales, los cambios pasan desapercibidos. Por eso la colonoscopía de vigilancia en la colitis ulcerativa es diferente a una colonoscopía normal: el médico toma múltiples biopsias en todas las zonas del colon, aunque todo se vea normal, para poder analizarlas en el microscopio.”
(No — and that is the most important point. Dysplastic cells are often in mucosa that looks normal from the outside. In common colon cancer not related to colitis, there is a visible polyp that the doctor can directly see with the colonoscope and remove. But in ulcerative colitis, the dysplastic changes can be distributed throughout the mucosa of the colon, in areas that look completely normal. If systematic biopsies are not taken from those apparently normal areas, the changes go undetected. That is why surveillance colonoscopy in ulcerative colitis is different from a regular colonoscopy: the doctor takes multiple biopsies in all areas of the colon, even though everything looks normal, to be able to analyze them under the microscope.)
Alejandro: “¿Y qué tan grande es el riesgo para Marco?”
(And how large is the risk for Marco?)
“Marco tiene colitis extensa — la que cubre todo el colon — y fue diagnosticado a los nueve años. Eso pone a Marco en una categoría de riesgo más alto que alguien con colitis limitada a una parte del colon. Los estudios muestran que las personas con colitis extensa de larga duración tienen un riesgo de cáncer colorrectal de dos a cinco veces más que la población general, y ese riesgo sube con los años de enfermedad. No sube solo cuando hay brotes — sube con los años, incluyendo los años buenos. Por eso las guías internacionales de colitis ulcerativa recomiendan colonoscopías de vigilancia cada uno a dos años a partir del octavo año del diagnóstico en pacientes con colitis extensa. Marco tiene seis años de diagnóstico — estamos empezando el proceso un poco antes de la marca de ocho años porque tuvo pancolitis y tuvo brotes severos al inicio.”
(Marco has extensive colitis — the kind that covers all of the colon — and was diagnosed at age nine. That puts Marco in a higher risk category than someone with colitis limited to one part of the colon. Studies show that people with longstanding extensive colitis have a two- to five-times higher colorectal cancer risk than the general population, and that risk rises with years of disease. It does not rise only when there are flares — it rises with the years, including the good years. That is why the international guidelines for ulcerative colitis recommend surveillance colonoscopies every one to two years starting from the eighth year of diagnosis in patients with extensive colitis. Marco has six years since diagnosis — we are starting the process a bit before the eight-year mark because he had pancolitis and had severe flares initially.)
Rosa: “Si encontraran algo en la biopsia, ¿qué pasaría?”
(If they found something in the biopsy, what would happen?)
“Depende de lo que encuentren. Si encontramos displasia de bajo grado — los cambios más tempranos — en una zona aislada, muchas veces se puede tratar localmente o se vigila más de cerca. Si encontramos displasia de alto grado, la recomendación generalmente es cirugía preventiva para quitar el colon antes de que progrese a cáncer invasivo. Si encontramos mucosa completamente normal en todas las biopsias — que es lo que esperamos — eso nos confirma que Marco está bien y la próxima colonoscopía sería en uno a dos años. Pero esa confirmación solo la podemos dar con las biopsias — no podemos darla con el examen físico ni con los síntomas ni con los análisis de sangre.”
(It depends on what we find. If we find low-grade dysplasia — the earliest changes — in an isolated area, it can often be treated locally or monitored more closely. If we find high-grade dysplasia, the recommendation is generally preventive surgery to remove the colon before it progresses to invasive cancer. If we find completely normal mucosa in all the biopsies — which is what we expect — that confirms to us that Marco is well and the next colonoscopy would be in one to two years. But that confirmation can only be given with the biopsies — we cannot give it with physical examination or symptoms or blood tests.)
Marco looks up from his phone. “¿Y la colonoscopía me lo va a decir con seguridad?”
(And the colonoscopy will tell me with certainty?)
“Con la precisión que los estudios periódicos dan — sí. Ninguna prueba es perfecta, pero la colonoscopía sistemática con biopsias es el estándar de cuidado internacional para este tipo de vigilancia. Y el objetivo no es preocuparte — es exactamente lo contrario: confirmar que estás bien, y si hubiera algo, encontrarlo mientras es tratable. En la mayoría de los pacientes en tu situación, la colonoscopía de vigilancia muestra un intestino sano. Pero para poder decirte eso con confianza, necesitamos verlo.”
(With the precision that periodic studies give — yes. No test is perfect, but systematic colonoscopy with biopsies is the international standard of care for this type of surveillance. And the goal is not to worry you — it is exactly the opposite: to confirm that you are well, and if there were anything, to find it while it is treatable. In the majority of patients in your situation, the surveillance colonoscopy shows a healthy intestine. But to be able to tell you that with confidence, we need to see it.)
Scenario 3: Camila Vega-Cruz — Dallas, Texas
Pediatric IBD nurse Patricia Fuentes-Morales and the parents who cannot understand why a colonoscopy is needed when the blood tests are normal and their daughter feels well
Camila is nine years old. She was diagnosed with ileocolonic Crohn’s disease (L3, inflammatory B1) at age seven in Dallas. Her parents are Carmen Vega-Morales, thirty-seven, a beauty salon owner, and Ernesto Cruz-Torres, forty, a plumber. At diagnosis, her PCDAI was 38 (moderate disease), her CRP was 22 mg/L, and she had four loose stools per day with occasional nocturnal awakening. She was treated with exclusive enteral nutrition for eight weeks, then started on azathioprine 2 mg/kg/day for maintenance.
Over the following two years on azathioprine, Camila has had no symptomatic flares. At today’s visit, her parents report she eats well, has formed stools once to twice per day, and has no abdominal pain. Her serum CRP is 0.4 mg/L — completely normal. Her complete blood count and comprehensive metabolic panel are normal. However, her fecal calprotectin collected last week is 380 μg/g — elevated, indicating active mucosal inflammation. The gastroenterology team is recommending a colonoscopy to assess mucosal healing and determine whether the azathioprine dose is adequate or whether escalation is needed.
Carmen opens the visit with a clear concern: “Trajimos los resultados de los análisis y todo está normal. La protéina C reactiva está normal, los glóbulos blancos normales, todo. Camila come bien, no tiene dolor, va al baño normal. ¿Por qué necesita una colonoscopía si todo el mundo dice que está bien?”
(We brought the results of the tests and everything is normal. The C-reactive protein is normal, white cells normal, everything. Camila eats well, has no pain, goes to the bathroom normally. Why does she need a colonoscopy if everyone says she is well?)
Ernesto: “Y la calprotectina fecal — no sabemos bien qué es esa prueba. ¿Es tan importante como para hacerle una colonoscopía si todo lo demás está normal?”
(And the fecal calprotectin — we don't know well what that test is. Is it important enough to do a colonoscopy if everything else is normal?)
Nurse Patricia Fuentes-Morales sits down with the printed results. “Esa pregunta es exactamente la correcta, y quiero responderla bien porque entiendo por qué parece inconsistente — los análisis normales y Camila sin síntomas y aun así recomendamos la colonoscopía. La diferencia está en qué mide cada prueba y dónde está la inflamación que nos preocupa.”
(That is exactly the right question, and I want to answer it well because I understand why it seems inconsistent — the normal tests and Camila without symptoms and still we recommend the colonoscopy. The difference is in what each test measures and where the inflammation we are concerned about is.)
Carmen: “¿Dónde está entonces?”
(Where is it then?)
“La protéina C reactiva es producida por el hígado. El hígado la produce cuando recibe una señal desde la sangre de que hay inflamación importante en alguna parte del cuerpo — esa señal son las citoquinas, unas proteínas que circulan en la sangre cuando hay mucha actividad inflamatoria. Cuando Camila tuvo un brote fuerte al momento del diagnóstico — con CRP en 22 — había tanta actividad inflamatoria que el hígado la detectó y produjo CRP en cantidad. Pero la inflamación en la mucosa del intestino de Camila puede estar activa a un nivel más bajo, solo en la pared del intestino, sin producir suficientes citoquinas circulantes para que el hígado reaccione. En ese caso, la CRP está normal en la sangre, pero la inflamación sigue en el intestino.”
(C-reactive protein is produced by the liver. The liver produces it when it receives a signal from the blood that there is significant inflammation somewhere in the body — that signal is cytokines, proteins that circulate in the blood when there is a lot of inflammatory activity. When Camila had a strong flare at the time of diagnosis — with CRP at 22 — there was so much inflammatory activity that the liver detected it and produced CRP in quantity. But the inflammation in the mucosa of Camila's intestine can be active at a lower level, only in the bowel wall, without producing enough circulating cytokines for the liver to react. In that case, CRP is normal in the blood, but the inflammation continues in the intestine.)
Ernesto: “¿Y la calprotectina fecal mide la inflamación directamente en el intestino?”
(And fecal calprotectin directly measures the inflammation in the intestine?)
“Exactamente. La calprotectina es una proteína que está dentro de los glóbulos blancos que se llaman neutrófilos. Cuando hay inflamación activa en la mucosa del intestino, esos neutrófilos van hacia el intestino y liberan su calprotectina ahí. Esa calprotectina se mezcla con las heces y sale en las deposiciones. Al medir la calprotectina en las heces, estamos midiendo directamente cuántos neutrófilos activos hay en el intestino de Camila en este momento. Es una ventana directa hacia la mucosa del intestino — sin depender del hígado, sin depender de los síntomas.”
(Exactly. Calprotectin is a protein that is inside white blood cells called neutrophils. When there is active inflammation in the intestinal mucosa, those neutrophils go to the intestine and release their calprotectin there. That calprotectin mixes with the stool and comes out in the bowel movements. By measuring calprotectin in the stool, we are directly measuring how many active neutrophils are in Camila's intestine right now. It is a direct window into the intestinal mucosa — without depending on the liver, without depending on symptoms.)
Carmen: “¿Y 380 es alto?”
(And 380 is high?)
“Sí. En niños con la enfermedad de Crohn, una calprotectina por encima de doscientos cincuenta a trescientos es consistente con inflamación mucosal activa en los estudios. La calprotectina de Camila de 380 nos dice que hay neutrófilos activos en su intestino en una cantidad que en estudios pediátricos se asocia con inflamación visible en la colonoscopía — erosiones, úlceras pequeñas, mucosa enrojecida y friable. Eso está pasando aunque la CRP esté normal y aunque Camila no sienta nada.”
(Yes. In children with Crohn's disease, a calprotectin above two hundred fifty to three hundred is consistent with active mucosal inflammation in the studies. Camila's calprotectin of 380 tells us that there are active neutrophils in her intestine in a quantity that in pediatric studies is associated with visible inflammation on colonoscopy — erosions, small ulcers, reddened and friable mucosa. That is happening even though CRP is normal and even though Camila feels nothing.)
Ernesto: “¿Por qué no tiene síntomas si hay inflamación?”
(Why does she have no symptoms if there is inflammation?)
“Porque los síntomas de la enfermedad de Crohn vienen cuando la inflamación es suficientemente intensa y extensa para alterar la función del intestino — para acelerar el tránsito, para producir sangrado visible, para causar espasmos dolorosos. La inflamación mucosal de menor intensidad puede dañar la pared del intestino desde adentro sin interrumpir el tránsito normal. Camila puede ir al baño con deposiciones formadas y sin dolor mientras pequeñas úlceras en la mucosa del íleon y del colon van produciendo tejido cicatricial que con el tiempo estrechará el intestino. Ese es el proceso que queremos interrumpir mientras todavía hay tiempo.”
(Because the symptoms of Crohn's disease come when inflammation is intense and extensive enough to alter bowel function — to accelerate transit, to produce visible bleeding, to cause painful spasms. Lower-intensity mucosal inflammation can damage the bowel wall from the inside without interrupting normal transit. Camila can go to the bathroom with formed stools and no pain while small ulcers in the mucosa of the ileum and colon are producing scar tissue that over time will narrow the intestine. That is the process we want to interrupt while there is still time.)
Carmen: “¿Y la colonoscopía qué nos va a decir exactamente?”
(And what exactly will the colonoscopy tell us?)
“Nos va a decir si la mucosa del intestino de Camila está cicatrizada — si no hay úlceras ni erosiones ni signos de inflamación activa cuando el médico lo ve directamente. Eso se llama curación de la mucosa, y es la meta del tratamiento en la enfermedad de Crohn en niños. Si la colonoscopía muestra curación de la mucosa a pesar de la calprotectina elevada, necesitamos revisar si la muestra de calprotectina fue representativa. Pero si la colonoscopía muestra inflamación activa visible — que es lo que esperamos encontrar dada la calprotectina — el gastroenterólogo de Camila puede ajustar el tratamiento: aumentar la dosis del azatioprina, medir los niveles del metabolito, o considerar agregar un biología si el azatioprina no es suficiente. La curación de la mucosa — confirmada por colonoscopía — es el único resultado que se asocia con menor riesgo de cirugía y mejor calidad de vida a largo plazo en los niños con la enfermedad de Crohn. Los síntomas son el punto de partida, no el punto de llegada.”
(It will tell us whether Camila's intestinal mucosa is healed — whether there are no ulcers or erosions or signs of active inflammation when the doctor sees it directly. That is called mucosal healing, and it is the treatment goal in Crohn's disease in children. If the colonoscopy shows mucosal healing despite the elevated calprotectin, we need to review whether the calprotectin sample was representative. But if the colonoscopy shows visible active inflammation — which is what we expect to find given the calprotectin — Camila's gastroenterologist can adjust the treatment: increase the azathioprine dose, measure the metabolite levels, or consider adding a biologic if azathioprine is not sufficient. Mucosal healing — confirmed by colonoscopy — is the only outcome that is associated with lower surgical risk and better long-term quality of life in children with Crohn's disease. Symptoms are the starting point, not the endpoint.)
Ernesto: “Entonces si los síntomas están bien pero la calprotectina está alta y la colonoscopía muestra inflamación, ¿la meta del tratamiento no se ha logrado todavía?”
(So if symptoms are well but calprotectin is high and colonoscopy shows inflammation, the treatment goal has not been achieved yet?)
“Exactamente eso. En la terminología médica, lo que tiene Camila ahora se llama remisión clínica — sin síntomas. Pero la meta del tratamiento moderno de la enfermedad de Crohn en niños es llegar a remisión profunda: sin síntomas Y con mucosa cicatrizada Y con calprotectina normal. Camila tiene la primera parte pero la calprotectina y posiblemente la colonoscopía nos van a decir que la segunda y tercera parte todavía están pendientes. Con el ajuste del tratamiento adecuado, es completamente posible llegar ahí.”
(Exactly that. In medical terminology, what Camila has now is called clinical remission — without symptoms. But the treatment goal of modern Crohn's disease management in children is to reach deep remission: without symptoms AND with healed mucosa AND with normal calprotectin. Camila has the first part but the calprotectin and possibly the colonoscopy will tell us that the second and third parts are still pending. With the right treatment adjustment, it is completely possible to get there.)
Carmen nods and puts down her phone. “Entiendo. El análisis de sangre nos decía cómo está su cuerpo en general. La calprotectina nos dice cómo está su intestino en específico. Y solo la colonoscopía puede confirmar si el intestino por dentro está bien.”
(I understand. The blood test was telling us how her body is in general. Calprotectin tells us how her intestine specifically is. And only the colonoscopy can confirm whether the intestine from the inside is well.)
“Exactamente así. Tres niveles de información, tres instrumentos diferentes. Cuando los tres coinciden — sin síntomas, calprotectina normal, colonoscopía con mucosa cicatrizada — ese es el resultado que más protege a Camila a largo plazo. Hoy solo tenemos el primero. La colonoscopía nos va a dar el tercero, y ajustaremos el tratamiento hasta que tengamos los tres.”
(Exactly so. Three levels of information, three different instruments. When all three coincide — no symptoms, normal calprotectin, colonoscopy with healed mucosa — that is the outcome that most protects Camila long-term. Today we only have the first. The colonoscopy will give us the third, and we will adjust treatment until we have all three.)
Frequently asked questions
How do pediatric IBD clinic nurses explain to Spanish-speaking parents why a biologic is needed when corticosteroids already achieved clinical remission in their child with Crohn’s disease?
The explanation requires distinguishing clinical remission (absence of symptoms) from mucosal healing (endoscopic and histological resolution of transmural inflammation) and demonstrating why only the latter prevents long-term complications in Crohn’s disease. Corticosteroids suppress the cytokine cascade producing abdominal pain, diarrhea, and systemic inflammation — they produce clinical remission. But they do not neutralize TNF-alpha, the central cytokine maintaining the transmural macrophage infiltrate and granuloma formation that drive progressive mural fibrosis leading to stricturing (bowel wall narrowing requiring surgery) and penetrating disease (fistula and abscess formation). Studies consistently show >50% of pediatric Crohn’s patients on steroid monotherapy without biologic maintenance develop structuring or penetrating complications within five years, often while in clinical remission. Anti-TNF biologics (infliximab, adalimumab) achieve transmural mucosal healing — endoscopic resolution of ulcers and erosions — which is the treatment target endorsed by ECCO/NASPGHAN pediatric guidelines because mucosal healing at one year is the strongest predictor of sustained remission, reduced surgical rates, and reduced hospitalization. The key Spanish frame: prednisone silenced the alarm but did not put out the fire; infliximab reaches the deep layers where the fire was burning.
How do pediatric IBD clinic nurses explain to Spanish-speaking parents why surveillance colonoscopy is required for their child with ulcerative colitis who has been in complete remission for years?
The explanation requires distinguishing the symptomatic pathway of UC flares from the asymptomatic molecular pathway of UC-associated dysplasia. Ulcerative colitis-associated dysplasia develops through chronic oxidative DNA damage from reactive oxygen species produced by mucosal neutrophils and macrophages during repeated inflammatory cycles — a process that accumulates even during periods of clinical remission. The resulting microsatellite instability and tumor suppressor gene loss (TP53, APC, SMAD4, CDKN2A) produce field-change dysplasia distributed across the colonic mucosa in endoscopically normal-appearing epithelium, without producing abdominal pain, urgency, or rectal bleeding. The cumulative colorectal cancer risk in longstanding extensive UC is 2 to 5 times the background rate after 8 to 10 years of disease, regardless of symptomatic status. Surveillance colonoscopy with systematic biopsies is the only method to detect dysplasia before progression to invasive carcinoma. Current NASPGHAN/ACG guidelines recommend surveillance every 1 to 2 years from 8 years after diagnosis in extensive colitis. The key Spanish frame: the disease has two separate processes — one that produces symptoms (flares) and one that silently alters DNA in mucosal cells over years. Only colonoscopy with biopsies can see the second.
How do pediatric IBD clinic nurses explain to Spanish-speaking parents why their child with Crohn’s disease needs a colonoscopy when CRP is normal and stools are formed?
The explanation requires distinguishing what serum CRP measures (systemic inflammation via circulating IL-6 triggering hepatic acute-phase protein synthesis) from what fecal calprotectin measures (local mucosal neutrophil activity in the intestinal lumen). Mucosal neutrophil inflammation in Crohn’s-affected bowel segments can be active at a level producing progressive mural fibrosis and complication risk without generating enough systemic IL-6 to elevate serum CRP. Azathioprine can suppress symptomatic disease and normalize CRP while leaving residual active mucosal disease detectable only by calprotectin and endoscopy. Fecal calprotectin >250 μg/g in pediatric Crohn’s correlates with active endoscopic disease with sensitivity ~70–80% and specificity 80–90%. A calprotectin of 380 μg/g in an asymptomatic child with normal CRP indicates incomplete treatment response, not remission — the treatment target (mucosal healing) has not been achieved. Colonoscopy confirms active mucosal disease, guides treatment escalation (azathioprine dose optimization, biologic addition), and establishes the mucosal healing baseline. The key Spanish frame: three levels of information (symptoms, blood CRP, fecal calprotectin) measure three different things; colonoscopy is the only tool that directly confirms whether the intestinal lining is healed.
What are the key clinical Spanish phrases for explaining biologic escalation, surveillance colonoscopy, and fecal calprotectin monitoring to Spanish-speaking families in the pediatric IBD clinic?
For biologic escalation after steroid-induced remission: “La prednisona controló los síntomas, pero la inflamación en la enfermedad de Crohn está en todas las capas de la pared del intestino, no solo en la superficie” (prednisone controlled the symptoms, but inflammation in Crohn’s disease is in all layers of the bowel wall, not just the surface). “Sin el biológico, esa inflamación profunda puede seguir produciendo cicatrices en la pared del intestino aunque Lucía no sienta nada” (without the biologic, that deep inflammation can continue producing scarring even if Lucía feels nothing). “La meta no es que se sienta bien — la meta es que la colonoscopía muestre el intestino completamente cicatrizado por dentro” (the goal is not to feel well — the goal is that colonoscopy shows the intestine completely healed from the inside). For surveillance colonoscopy in asymptomatic UC: “Hay un proceso diferente a los brotes que puede ocurrir en las células del intestino después de años de colitis, aunque el paciente no sienta nada” (there is a different process from flares that can occur in the intestinal cells after years of colitis, even when the patient feels nothing). “Esos cambios no producen síntomas — la única manera de encontrarlos es con la colonoscopía y las biopsias” (those changes do not produce symptoms — the only way to find them is with colonoscopy and biopsies). For calprotectin vs. CRP: “La proteína C reactiva mide la inflamación en el cuerpo en general — puede estar normal aunque haya inflamación activa en el intestino” (CRP measures inflammation in the body in general — it can be normal even with active inflammation in the intestine). “La calprotectina fecal mide directamente los glóbulos blancos activos en el intestino — es una ventana hacia la mucosa que la sangre no puede dar” (fecal calprotectin directly measures active white blood cells in the intestine — it is a window into the mucosa that blood tests cannot provide).
What are the most important communication challenges specific to Spanish-speaking families in the pediatric IBD outpatient clinic that standard handouts do not address?
Three structural disconnects drive the communication challenges in the pediatric IBD outpatient clinic. First: the gap between the family’s direct experience that corticosteroids worked (the child’s symptoms resolved, prednisone achieved what it said it would achieve) and the clinical claim that this working was insufficient (the disease’s natural history remained intact at the transmural level). A family that has watched their child transform from sick to well on prednisone has earned their confidence in that treatment response. The nurse’s task is to honor that real clinical success while adding a layer the family cannot observe: the difference between surface-level symptom control and deep mucosal healing, and the cumulative structural damage that continues invisibly in the bowel wall during clinical remission in the absence of biologic therapy. The family that understands this distinction will maintain biologic adherence during the inevitable periods when their child feels completely well and the treatment seems unnecessary. Second: the family’s mental model of UC as a symptomatic disease (well when in remission, sick when flaring) is entirely correct for the flare-surveillance question but entirely wrong for the dysplasia-surveillance question. These two surveillance purposes require two different conceptual frameworks, and standard UC education overwhelmingly focuses on the first. The bilingual nurse who can introduce the second framework — the molecular pathway by which years of cumulative oxidative DNA damage in mucosal cells can progress toward dysplasia without ever producing a symptomatic flare — gives the family a reason to accept colonoscopy surveillance that their symptomatic experience of remission cannot provide. Third: the family’s trust in serum CRP as the definitive disease activity marker is reasonable, because CRP elevation has historically tracked with disease flares in their child’s history. When CRP is normal and symptoms are absent, the family has two concordant signals that the disease is controlled. The fecal calprotectin elevation is a discordant third signal that requires explaining why it carries independent information not captured by the other two. The nurse who can distinguish the informational content of systemic inflammation markers (CRP: liver-mediated response to circulating IL-6) from local mucosal inflammation markers (calprotectin: direct measure of intestinal neutrophil activity) — and explain that these two things can diverge when disease activity operates below the systemic threshold — gives the family a framework for accepting a management recommendation that appears to contradict what their trusted test results are telling them.
Pediatric inflammatory bowel disease clinic nursing requires managing the gap between how the child looks and functions and how the bowel wall is doing at the histological level across three clinical domains simultaneously. The family that leaves Lucía’s appointment understanding why mucosal healing — not clinical remission — is the treatment target will maintain biologic adherence during the years when Lucía feels entirely well and the infusions seem like excess. The family that understands why UC-associated dysplasia develops asymptomatically through a mechanism entirely different from flares will accept surveillance colonoscopy without needing Marco to feel sick first. The family that understands why serum CRP and fecal calprotectin measure different things at different levels will trust Camila’s colonoscopy recommendation even though the blood test told them everything was fine.
In all three conversations, the families started from a reasonable, internally consistent model of their child’s disease — based on what they observed, what they read, and what their prior clinical experiences confirmed — and arrived at a different understanding not because they were wrong to ask but because the clinical team added the biological layer their intuition could not independently access. The bilingual nurse who can deliver that layer in Spanish, in the idiom and directness the family uses at home, in the time available between patients in a busy pediatric GI clinic, is providing something that no translated handout and no English-only explanation can replicate.
For related reading on complex communication in pediatric specialty clinics with long-term medication and monitoring demands, see Spanish for pediatric chronic kidney disease clinic nurses (pre-emptive transplant referral timing, protein restriction, phosphate binder initiation) and Spanish for pediatric pulmonary arterial hypertension clinic nurses (triple combination therapy, catheterization vs. echocardiography, transplant listing timing). For the adult IBD outpatient setting covering similar communication challenges in adult patients, see Spanish for IBD clinic nurses. For communication challenges in pediatric oncology and chronic disease transitions, see Spanish for pediatric cystic fibrosis clinic nurses. The 50 Spanish ED phrases PDF covers the acute presentations that often precede the IBD diagnosis conversations. Our full free practice library is available without login. For more long-form clinical-Spanish posts, visit the ClinicaLingo blog.